Carfilzomib and Overdose - a phase IV clinical study of FDA data

Summary:

Overdose is reported as a side effect among people who take Carfilzomib (carfilzomib), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Dexamethasone, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Overdose when taking Carfilzomib. It is created by eHealthMe based on reports of 13,484 people who have side effects when taking Carfilzomib from the FDA, and is updated regularly.

What is Carfilzomib?

Carfilzomib has active ingredients of carfilzomib. eHealthMe is studying from 13,486 Carfilzomib users. Check the latest studies of Carfilzomib.

What is Overdose?

Overdose is found to be associated with 2,212 drugs and 2,475 conditions by eHealthMe. Check the latest studies of Overdose.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

13,484 people reported to have side effects when taking Carfilzomib.
Among them, 23 people (0.17%) have Overdose.

Among these 23 people:

How long have people been on Carfilzomib when they have Overdose? *

What is the gender of people who have Overdose when taking Carfilzomib? *

female: 13.64 %
male: 86.36 %

What is the age of people who have Overdose when taking Carfilzomib? *

What are other drugs people take besides Carfilzomib? *

What are other side effects people have besides Overdose? *

Acute Kidney Failure: 6 people, 26.09%
Thrombotic Microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury): 5 people, 21.74%
Pneumonia: 5 people, 21.74%
High Blood Pressure: 4 people, 17.39%
Arrhythmias (irregular heartbeat): 4 people, 17.39%
Depressed Level Of Consciousness: 4 people, 17.39%
Disturbance In Attention: 4 people, 17.39%
General Physical Health Deterioration (weak health status): 4 people, 17.39%
Fever: 4 people, 17.39%
Pulmonary Oedema (fluid accumulation in the lungs): 4 people, 17.39%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 17 people, 73.91%
Plasmacytoma (neoplasm of plasma cells (usually in bone marrow)): 6 people, 26.09%
Sepsis (a severe blood infection that can lead to organ failure and death): 4 people, 17.39%
Urinary Tract Infection Enterococcal: 3 people, 13.04%
Bacterial Infection: 3 people, 13.04%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 2 people, 8.70%
High Blood Pressure: 2 people, 8.70%
Klebsiella Bacteraemia (klebsiella bacteria in blood after infection to lungs): 2 people, 8.70%
Klebsiella Infection: 2 people, 8.70%
Kidney Infection (Pyelonephritis): 2 people, 8.70%

* Approximation only. Some reports may have incomplete information.

Do you take Carfilzomib and have Overdose?

- Check whether Overdose is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Carfilzomib:

Carfilzomib (13,486 reports)

Overdose treatments and more:

Overdose (229,245 reports)

Browse all side effects of Carfilzomib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Overdose:

Overdose (2,212 drugs)

Browse all the conditions that are associated with Overdose:

Overdose (2,475 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on carfilzomib (the active ingredients of Carfilzomib) and Carfilzomib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.